Business Wire

Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents

Share

AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain

Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy.

“Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.”

Maestro Agents advance the customer journey from conversational AI to decision-based agentic supply chain orchestration. Unlike generic AI assistants that sit outside the process, Maestro Agents are embedded in live planning environments where they understand context, constraints, and trade-offs to plan with you, not for you. With Maestro Agents now live, Kinaxis will continue to expand the Maestro ecosystem with Maestro Agent Studio (now in limited availability) and the arrival of an agent marketplace in 2026, guiding customers through a phased path to realize the full potential of AI-driven orchestration.

“Today’s supply chains operate within an environment of constant volatility. Resilience and adaptability are no longer aspirational - they are mission-critical,” said Andrew Bell, Chief Product Officer at Kinaxis. “Maestro Agents bring explainable AI into the moments that matter for supply chain leaders and practitioners. As our customers continue to coordinate across processes and grow an ecosystem of Kinaxis and partner-built agents, now they can unlock new levels of speed, resilience, and adaptability.”

Proven Value in Real-World Supply Chains

Early adopters describe Maestro Agents as game-changing by cutting hours of manual work and giving planners confidence to act faster with AI that understands their world.

“Flexibility and guardrails are essential if companies are going to trust and scale AI,” said Eric Thompson, Research Director, IDC. “With Maestro Agents, Kinaxis is showing what practical, explainable AI looks like in enterprise operations by embedding agentic capabilities directly into live planning environments so organizations can test, learn, and grow safely and effectively.”

Built to bring decision intelligence into the moment work happens, Maestro Agents turn analysis into action right inside the planning environment. For supply chain planners, they can now rely on agents to:

  • Bring AI into daily work by analyzing live data, flagging issues, and recommending next-best actions directly within Maestro, helping planners move from problem to decision in seconds.
  • Synthesize and unpack real-world constraints by factoring in supplier capacity, inventory levels, production schedules, and customer priorities to deliver recommendations that are achievable and aligned with business goals.
  • Make AI explainable and trustworthy with human-in-the-loop guardrails and clear reasoning that show why each action is recommended.
  • Free up time for higher-value work by automating reporting and routine analysis, enabling planners to focus on strategic decisions that improve performance and resilience and transforming how planners respond to disruption and make decisions in real time.

Customers are already leveraging the robust capabilities of Maestro Agents, and several enterprise organizations have proven how investments in early innovation are delivering significant real-world value within their supply chain environments:

  • A top-10 global pharmaceutical company boosted planner productivity by up to 10×, cutting the steps to identify inventory risks from 40 clicks to just 4 and surfacing insights in seconds instead of minutes or hours, driving significant efficiency gains across its planning process.
  • One of the world’s largest electronics manufacturers streamlined its reporting processes, cutting manual effort and empowering planners to save over 30 hours per month. With this time back, they were able to focus on higher-value initiatives that improved on-time delivery and elevated customer satisfaction.

These innovations represent the next step toward a connected, adaptive future where AI and human expertise orchestrate the world’s supply chains together.

To learn more about how Maestro Agents can accelerate your supply chain, visit kinaxis.com/aiagents.

About Kinaxis

Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities laws, including statements about future product capabilities, planned launches, anticipated benefits, and the expected performance or impact of Kinaxis Maestro Agents. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties are described in Kinaxis’ most recent Annual Information Form and other filings with Canadian securities regulators. Kinaxis disclaims any obligation to update or revise these statements, except as required by law.

Source: Kinaxis Inc

View source version on businesswire.com: https://www.businesswire.com/news/home/20251017746583/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye